Severe combined immunodeficiences: New and old scenarios

International Reviews of Immunology

Volumn 31, Issue 1, 2012, Pages 43-65

  Aloj, Giuseppina ^a   Giardino, Giuliana ^a   Valentino, Leopoldo ^a   Maio, Filomena ^a   Gallo, Vera ^a   Esposito, Tiziana ^a   Naddei, Roberta ^a   Cirillo, Emilia ^a   Pignata, Claudio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Adenosine deaminase; DNA repair defect; Nude SCID; Primary immunodeficiencies; SCID; T cell ontogeny

Indexed keywords

ADENOSINE DEAMINASE; CORONIN 1A; DEDICATOR OF CYTOKINESIS 8; DOUBLE STRANDED DNA; INTERLEUKIN 7 RECEPTOR ALPHA; JANUS KINASE 3; KHELLIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDES AND PROTEINS; PROTEIN KINASE ZAP 70; PURINE NUCLEOSIDE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ADENOSINE DEAMINASE DEFICIENCY; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL FEATURE; DISEASE ASSOCIATION; DOUBLE STRANDED DNA BREAK; FAILURE TO THRIVE; GENE MUTATION; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOPATHOLOGY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 DEFICIENCY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2 DEFICIENCY; NATURAL KILLER CELL; NONHUMAN; OPPORTUNISTIC INFECTION; PRIMARY IMMUNODEFICIENCY; PRIORITY JOURNAL; PURINE NUCLEOSIDE PHOSPHORYLASE DEFICIENCY; RETICULAR DYSGENESIS; SEVERE COMBINED IMMUNODEFICIENCY; T LYMPHOCYTE;

ANIMALS; EARLY DETECTION OF CANCER; HUMANS; INFECTION; PHENOTYPE; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 84856116603     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2011.644607     Document Type: Article

References (181)

1. Notarangelo LD, Fischer A,Geha RS, et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol. 2009;124:1161-1178.
2. Fischer A, Le Deist F,Hacein-Bey-Abina S, et al. Severe combined immunodeficiency: amodel disease for molecular immunology and therapy. Immunol Rev. 2005;203:98-109. (Pubitemid 40179696)
3. PalmerK,Green TD,Roberts JL, et al.Unusual clinical andimmunologicmanifestations of transplacentally acquiredmaternal T cells in severe combined immunodeficiency. J Allergy Clin Immunol. 2007;120:423-428. (Pubitemid 47102368)
4. Puck JM, Pepper AE,Henthorn PS, et al.Mutation analysis of IL2RGin human X-linked severe combined immunodeficiency. Blood. 1997;89:1968-1977. (Pubitemid 27132112)
5. Notarangelo LD,Giliani S,Mazza C, et al.Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the gamma(c)-JAK3 signaling pathway as amodel. Immunol Rev. 2000;178:39-48. (Pubitemid 32095218)
6. Leonard WJ, Noguchi M, Russell SM, McBride OW. The molecular basis of X-linked severe combined immunodeficiency: the role of the interleukin-2 receptor gamma chain as a common gamma chain, gamma c. Immunol Rev. 1994;138:61-86. (Pubitemid 24147416)
7. Du C, Guan Q, Yin Z, Zhong R, Jevnikar AM. IL-2-mediated apoptosis of kidney tubular epithelial cells is regulated by the caspase-8 inhibitor c-FLIP. Kidney Int. 2005;67:1397-1409. (Pubitemid 40463116)
8. Ozawa A, Tada H, Sugawara Y, et al. Endogenous IL-15 sustains recruitment of IL-2Rbeta and common gamma and IL-2-mediated chemokine production in normal and inflamed human gingival fibroblast. J Immunol. 2004;173:5180-5188. (Pubitemid 39387801)
9. Adriani M, Garbi C, Amodio G, et al. Functional interaction of common gamma chain and growth hormone receptor signaling apparatus. J Immunol. 2006;177:6889-6895. (Pubitemid 44715054)
10. Amorosi S, Russo I, Amodio G, et al. The cellular amount of the common g-chain influences spontaneous or induced cell proliferation. J Immunol. 2009;182:3304-3309.
11. Kawamura M,McVicar DW, Johnston JA, et al.Molecular cloning of L-JAK, a Janus family proteintyrosine kinase expressed in natural killer cells and activated leukocytes. PNAS. 1994;91:6374-6378. (Pubitemid 24200663)
12. Rane SG, Reddy EP. JAK3: a novel JAK kinase associatedwith terminal differentiation ofhematopoietic cells. Oncogene. 1994;9:2415-2423. (Pubitemid 24228695)
13. Cacalano NA, Migone TS, Bazan F, et al. Autosomal SCID caused by a point mutation in the Nterminus of Jak3:mapping of the Jak3-receptor interaction domain. EMBO J. 1999;18:1549-1558. (Pubitemid 29127068)
14. Notarangelo L. Immunodeficiencies caused by genetic defects in protein kinases. Curr Opin Immunol. 1996;8:448-453. (Pubitemid 26280769)
15. Pignata C, Prasad KVS, Hallek M, et al. Phosphorylation of src family lck tyrosine kinase following interleukin-12 activation of human natural killer cells. Cell Immunol. 1995;165:211-216.
16. Lyszkiewicz M, Pajtasz-Piasecka E. Contribution of interleukin 2 and interleukin 12 receptors in signal transduction during cell activation of the immune system. Postepy Hig Med Dosw. 2002;56:707-731.
17. Ambrosio R, Fimiani G, Monfregola J, et al. The structure of human STAT5A and B genes reveals two regions of nearly identical sequence and an alternative tissue specific STAT5B promoter. Gene. 2002;285:311-318. (Pubitemid 34246348)
18. Yao Z, Cui Y, Watford WT, et al. Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci U S A. 2006;103:1000-1005. (Pubitemid 43212211)
19. Schumacher RF, Mella P, Badolato R, et al. Complete genomic organization of the human JAK3 gene andmutation analysis in severe combined immunodeficiency by single-strand conformation polymorphism. HumGenet. 2000;106:73-79. (Pubitemid 30156397)
20. Buckley RH, Schiff RI, Schiff SE, et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr. 1997;130:378-387. (Pubitemid 27492681)
21. Mella P, Schumacher RF, Cranston T, de Saint Basile G, Savoldi G, Notarangelo L. Eleven novel JAK3 mutations in patients with severe combined immunodeficiency-including the first patients withmutations in the kinase domain. HumMutat. 2001;18:355-356.
22. Notarangelo L, Mella P, Jones A, et al. Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency. HumMutat. 2001;18:255-263. (Pubitemid 32916857)
23. Fischer A. Severe combined immunodeficiencies. Immunodefic Rev. 1992;3:83-100.
24. Stephan JL, Vlekova V, LeDeist F, et al. Severe combined immunodeficiency: a retrospective singlecentre study of clinical presentation and outcome in 117 patients. J Pediatr. 1993;123:564-572. (Pubitemid 23287526)
25. Di Santo JP, Rieux-Laucat F, Dautry-Varsat A, Fischer A, de Saint Basile G. Defective human interleukin 2 receptor g chain in an atypical X chromosome-linked severe combined immunodeficiency with peripheral T cells. Proc Natl Acad Sci U S A. 1994;91:9466-9470. (Pubitemid 24297935)
26. Schmalstieg FC, Leonard WJ, Noguchi M, et al. Missense mutation in exon 7 of the common gamma chain gene causes amoderate formof X-linked combined immunodeficiency. J Clin Invest. 1995;95:1169-1173.
27. LynchM, Baker E, Park LS, Sutherland GR, Goodwin RG.The interleukin-7 receptor gene is at 5p13. HumGenet. 1992;89:566-568.
28. Kang J, Der SD. Cytokine functions in the formative stages of a lymphocyte's life. Curr Opin Immunol. 2004;16:180-190. (Pubitemid 38328719)
29. Yu Q, Erman B, Bhandoola A, Sharrow SO, Singer A. In vitro evidence that cytokine receptor signals are required for differentiation of double positive thymocytes into functionallymatureCD8+ T cells. J ExpMed. 2003;197:475-487. (Pubitemid 36278603)
30. Giliani S,Mori L, De Saint Basile G, et al. Interleukin-7 receptor a (IL-7Ra) deficiency: cellular and molecular bases. Analysis of clinical, immunological, and molecular features in 16 novel patients. Immunol Rev. 2005;203:110-126. (Pubitemid 40179697)
31. Puel A, Leonard WJ. Mutations in the gene for the IL-7 receptor result in T(-)B(+)NK(+) severe combined immunodeficiency disease. Curr Opin Immunol. 2000;12:468-473. (Pubitemid 30410355)
32. Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet. 1998;20:394-397. (Pubitemid 28541642)
33. Nyhan WL. Disorders of purine and pyrimidine metabolism.Mol GenetMetab. 2005;86:25-33. (Pubitemid 41417680)
34. HershfieldM. PEG-ADA: an alternative to haploidentical bonemarrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. HumMutat. 1995;5:107-112.
35. Vihinen M, Arredondo-Vega FX, Casanova JL, et al. Primary immunodeficiency mutation databases. Adv Genet. 2001;43:103-188.
36. Malacarne F, Benicchi T, Notarangelo LD, et al. Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients. Eur J Immunol. 2005;35:3376-3386. (Pubitemid 41672541)
37. Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science. 1993;261:466-469. (Pubitemid 23276554)
38. HershfieldM. Adenosine deaminase deficiency. In: Pagon RA, Bird TD, Dolan CR, Stephens K, eds. Gene Reviews [Internet]. Seattle (WA): U.S. National Library ofMedicine; 2009.
39. Santisteban I, Arredondo-Vega FX, Kelly S, et al. Novel splicing, missense, and deletion mutations in seven adenosine deaminase-deficient patients with late/delayed onset of combined immunodeficiency disease: contribution of genotype to phenotype. J Clin Invest. 1993;92:2291-2302. (Pubitemid 23333535)
40. Shovlin CL, Hughes JM, Simmonds HA, et al. Adult presentation of adenosine deaminase deficiency. Lancet. 1993;341:1471. (Pubitemid 23161466)
41. Arredondo-Vega FX, Santisteban I, Daniels S, Toutain S, Hershfield MS. Adenosine deaminase deficiency: genotype-phenotype correlations based on expressed activity of 29 mutant alleles. Am J HumGenet. 1998;63:1049-1059. (Pubitemid 30418574)
42. Booth C, Hershfield M, Notarangelo L, et al. Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). Clin Immunol. 2007;123:139-147. (Pubitemid 46590067)
43. AiutiA,Cattaneo F,Galimberti S, et al.Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl JMed. 2009;360:447-458.
44. Gaspar HB, Bjorkegren E, Parsley K, et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use ofmild preconditioning.MolTher. 2006;14:505-513. (Pubitemid 44339393)
45. Pannicke U, Tuchschmid P, Friedrich W, Bartram CR, Schwarz K. Two novel missense and frameshift mutations in exons 5 and 6 of the purine nucleoside phosphorylase (PNP) gene in a severe combined immunodeficiency (SCID) patient. Hum Genet. 1996;98:706-709. (Pubitemid 26387962)
46. Aytekin C, Germeshausen M, Tuygun N, Tanir G, Dogu F, Ikinciogullari A. Kostmann disease with developmental delay in three patients. Eur J Pediatr. 2010;169:759-762.
47. Alangari A, Al-Harbi A, Al-Ghonaium A, Santisteban I, Hershfield M. Purine nucleoside phosphorylase deficiency in two unrelated Saudi patients. Ann SaudiMed. 2009;29:309-312.
48. Dror Y, GrunebaumE, Hitzler J, et al. Purine nucleoside phosphorylase deficiency associated with a dysplasticmarrowmorphology. Pediatr Res. 2004;55:472-477. (Pubitemid 38240827)
49. MarkertML. Purine nucleoside phosphorylase deficiency. Immunodefic Rev. 1991;3:45-81.
50. GrunebaumE, Zhang J, Roifman CM.Novelmutations and hot-spots in patientswith purine nucleoside phosphorylase deficiency. Nucleosides Nucleotides Nucleic Acids. 2004;23:1411-1415. (Pubitemid 39625935)
51. Bassing CH, SwatW, Alt FW.Themechanism and regulation of chromosomal V(D)J recombination. Cell. 2002;109:S45-S55.
52. Schwarz K, Gauss GH, Ludwig L, et al. RAG mutations in human B cell-negative SCID. Science. 1996;274:97-99. (Pubitemid 26332732)
53. Ehl S, Schwarz K, Enders A, et al. A variant of SCID with specific immune responses and predominance of gamma delta T cells. J Clin Invest. 2005;115:3140-3148. (Pubitemid 41567578)
54. De Villartay JP, Lim A, Al-Mousa H, et al. A novel immunodeficiency associated with hypomorphic RAG1mutations and CMV infection. J Clin Invest. 2005;115:3291-3299. (Pubitemid 41567594)
55. Schuetz C,Huck K,Gudowius S, et al. An immunodeficiency diseasewith RAGmutations and granulomas. N Engl JMed. 2008;8:2030-2038.
56. Niehues T, Perez-Becker R, Schuetz C. More than just SCID-the phenotypic range of combined immunodeficiencies associated withmutations in the recombinase activating genes (RAG) 1 and 2. Clin Immunol. 2010;135:183-192.
57. Rivera-Munoz P, Malivert L, Derdouch S, et al. DNA repair and the immune system: from V(D)J recombination to aging lymphocytes. Eur J Immunol. 2007;37:S71-S82. (Pubitemid 350131270)
58. Huang Y, GiblinW, Kubec M, et al. Impact of a hypomorphic Artemis disease allele on lymphocyte development, DNA end processing, and genome stability. J ExpMed. 2009;206:893-908.
59. + severe combined immunodeficiency caused by a LIG4mutation. J Clin Invest. 2006;116:137-145. (Pubitemid 43121798)
60. Emile JF, Geissmann F,Martin OC, et al. Langerhans cell deficiency in reticular dysgenesis. Blood. 2000;96:58-62. (Pubitemid 30456450)
61. Pannicke U, Hönig M, Hess I, et al. Reticular dysgenesis (aleukocytosis) is caused by mutations in the gene encoding mitochondrial adenylate kinase 2. Nat Genet. 2009;41:101-105.
62. Dzeja PP, Terzic A. Phosphotransfer networks and cellular energetics. J Exp Biol. 2003;206:2039-2047. (Pubitemid 36761807)
63. Schlauderer GJ, Proba K, Schulz GE. Structure of a mutant adenylate kinase ligated with an ATPanalogue showing domain closure over ATP. JMol Biol. 1996;256:223-227. (Pubitemid 26105586)
64. Köhler C, Gahm A, Noma T, Nakazawa A, Orrenius S, Zhivotovsky B. Release of adenylate kinase 2 from the mitochondrial intermembrane space during apoptosis. FEBS Lett. 1999;447:10-12. (Pubitemid 29134937)
65. Lagresle-Peyrou C, Six EM, Picard C, et al. Human adenylate kinase 2 deficiency causes a profound hematopoietic defect associated with sensorineural deafness. Nat Genet. 2009;41:106-111.
66. Chan AC, IwashimaM, Turck CW,Weiss A. ZAP-70: a 70 kD protein-tyrosine kinase that associates with the TCR zeta chain. Cell. 1992;71:649-662.
67. Hivroz C, Fischer A. Immunodeficiency diseases. Multiple roles for ZAP-70. Curr Biol. 1994;4:731-733.
68. Weiss A. T cell antigen receptor signal transduction: a tale of tails and cytoplasmic protein-tyrosine kinases. Cell. 1993;73:209-212. (Pubitemid 23123299)
69. Miosge LA and Goodnow CC. Genes, pathways and checkpoints in lymphocyte development and homeostasis. Immunol Cell Biol 2005;83:318-335. (Pubitemid 41044609)
70. ElderME. ZAP-70 and defects of T-cell receptor signaling. Semin Hematol. 1998;35:310-320. (Pubitemid 28477932)
71. + thymic selection in humans lacking Zap-70 kinase. Cell. 1994;76:947-958. (Pubitemid 24085331)
72. Turul T, Tezcan I, Artac H, et al. Clinical heterogeneity can hamper the diagnosis of patients with ZAP70 deficiency. Eur J Pediatr. 2009;168:87-93.
73. + T cells in peripheral blood and their skin infiltration in CD8 deficiency. Clin Exp Immunol. 1999;115:124-130. (Pubitemid 29030374)
74. Parry DE, Blumenthal J, Tomar RH,Horowitz SD, Elder ME, Gern GE. A 3-year-old boy with ZAP-70 deficiency, thrombocytopenia and ulcerative colitis. J Allergy Clin Immunol. 1996;97:390.
75. Zimmer J, Andr̀es E, Donato L, Hanau D, Hentges F, de la Salle H. Clinical and immunological aspects of HLA class I deficiency. Q JMed. 2005;98:719-727. (Pubitemid 41548549)
76. Grommé M, Neefjes J. Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways.Mol Immunol. 2002;39:181-202. (Pubitemid 35013511)
77. Pamer E, Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol. 1998;16:323-358. (Pubitemid 28183368)
78. + T cell responses to infectious agents, tumors, transplants, and vaccines. Adv Immunol. 1999;73:1-77. (Pubitemid 29300428)
79. York IA, Rock KL. Antigen processing and presentation by the class Imajor histocompatibility complex. Annu Rev Immunol. 1996;14:369-396. (Pubitemid 26130189)
80. Watts C, Powis S. Pathways of antigen processing and presentation. Rev Immunogenet. 1999;1:60-74.
81. de la Salle H, Zimmer J, Fricker D, et al. HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1. J Clin Invest. 1999;103:R9-R13. (Pubitemid 29122431)
82. Gadola SD, Moins-Teisserenc HT, Trowsdale J, Gross WL, Cerundolo V. TAP deficiency syndrome. Clin Exp Immunol. 2000;121:173-178. (Pubitemid 30659751)
83. De La Salle H, Hanau D, Fricker D, et al. Homozygous human TAP peptide transporter mutation in HLA class I deficiency. Science. 1994;266:1464.
84. Furukawa H,Murata S, Yabe T, et al. Splice acceptor sitemutation of the transporter associatedwith antigen processing-1 gene in human bare lymphocyte syndrome. J Clin Invest. 1999;103:755-758. (Pubitemid 29122430)
85. Moins-Teisserenc HT, Gadola SD, Cella M, et al. Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet. 1999;354:1598-1603. (Pubitemid 29515952)
86. de la Salle H, Saulquin X,Mansour I, et al. Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP). Clin Exp Immunol. 2002;128:525-531. (Pubitemid 34639316)
87. Furukawa H, Yabe T, Watanabe K, et al. Tolerance of NK and LAK activity for HLA class Ideficient targets in a TAP1-deficient patient (bare lymphocyte syndrome type I). Hum Immunol. 1999;60:32-40. (Pubitemid 29057854)
88. Donato L, de la Salle H, Hanau D, et al. Association of HLA class I antigen deficiency related to a TAP2 genemutation with familial bronchiectasis. J Pediatr. 1995;127:895-900. (Pubitemid 26003281)
89. Plebani A,Monafo V, Cattaneo R, et al. Defective expression of HLA class I and CD1a molecules in boy withMarfan-like phenotype and deep skin ulcers. J Am Acad Dermatol. 1996;35:814-818. (Pubitemid 26389444)
90. Yabe T, Kawamura S, Sato M, et al. A subject with a novel type I bare lymphocyte syndrome has tapasin deficiency due to deletion of 4 exons by Alu-mediated recombination. Blood. 2002;100:1496-1498. (Pubitemid 34864312)
91. Ortmann B, Copeman J, Lehner PJ, et al. A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Science. 1997;277:1306-1309. (Pubitemid 27449083)
92. Schoenhals GJ, Krishna RM, Grandea AGr, et al. Retention of empty MHC class I molecules by tapasin is essential to reconstitute antigen presentation in invertebrate cells. EMBO J. 1999;18:743-753. (Pubitemid 29057259)
93. Herberg JA, Sgouros J, Jones T, et al. Genomic analysis of the Tapasin gene, located close to the TAP loci in the MHC. Eur J Immunol. 1998;28:459-467. (Pubitemid 28101720)
94. Grandea AGr, Van Kaer L. Tapasin: an ER chaperone that controlsMHC class I assembly with peptide. Trends Immunol. 2001;22:194-199. (Pubitemid 32673658)
95. Copeman J, Bangia N, Cross JC, Cresswell P. Elucidation of the genetic basis of the antigen presentation defects in the mutant cell line .220 reveals polymorphism and alternative splicing of the tapasin gene. Eur J Immunol. 1998;28:3783-3791. (Pubitemid 28510789)
96. Grandea AGr, Golovina TN, Hamilton SE, et al. Impaired assembly yet normal trafficking of MHC class Imolecules in Tapasinmutantmice. Immunity. 2000;13:213-222.
97. Garbi N, Tan P, Diehl AD, et al. Impaired immune responses and altered peptide repertoire in tapasin-deficientmice. Nat Immunol. 2000;1:234-238.
98. Klein C, Lisowska-Grospierre B, LeDeist F, Fischer A, Griscelli C. Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features, and outcome. J Pediatr. 1993;123:921-928. (Pubitemid 23353255)
99. ReithW, Steimle V, Lisowska-Grospierre B, Fischer A,Mach B.Molecular basis ofmajor histocompatibility class II deficiency. In: Ochs H, Puck J, Smith E, eds. Primary Immunodeficiency Diseases: AMolecular and Genetic Approach. New York: Oxford University Press; 1999: 167-180.
100. Griscelli C, Lisowska-Grospierre B, Mach B. Combined immunodeficiency with defective expression inMHCclass II genes. In: Rosen FS, SeligmanM, eds. Immunodeficiencies. Chur, Switzerland: Harwood Academic; 1993: 141-154.
101. Mach B, Steimle V,Martinez-Soria E and Reith W. Regulation of MHC class II genes: lessons froma disease. Annu Rev Immunol. 1996;14:301-331. (Pubitemid 26130187)
102. Elhasid R, Etzioni A. Major histocompatibility complex class II deficiency: a clinical review. Blood Rev. 1996;10:242-248. (Pubitemid 27042827)
103. Trowsdale J. Genomic structure and function in the MHC. Trends Genet. 1993;9:117-122. (Pubitemid 23098778)
104. Jameson SC, Hogquist KA, Bevan MJ. Positive selection of thymocytes. Annu Rev Immunol. 1995;13:93-126.
105. Viret C, Janeway CAJ. MHC and T cell development. Rev Immunogenet. 1999;1:91-104.
106. Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol. 1994;12:259-293. (Pubitemid 24140416)
107. Benoist C,Mathis D. Regulation ofmajor histocompatibility complex class II genes: X, Y and other letters of the alphabet. Annu Rev Immunol. 1990;8:681-715. (Pubitemid 20135643)
108. Ting JP, Baldwin AS. Regulation ofMHC gene expression. Curr Opin Immunol. 1993;5:8-16.
109. Boss JM. Regulation of transcription of MHC class II genes. Curr Opin Immunol. 1997;9:107-113. (Pubitemid 27095905)
110. Gladstone P, Pious D. Identification of a transacting function regulation HLA-DR expression in a DR-negative B cell variant. Somatic Cell Genet. 1980;6:285-298. (Pubitemid 10150624)
111. Accolla RS, Scarpellino L, Carra G, Guardiola J. Trans-acting element(s) operating across species barriers positively regulate expression of major histocompatibility complex class II genes. J Exp Med. 1985;162:1117-1133. (Pubitemid 16225109)
112. Moreno CS, Rogers EM, Brown JA, Boss JM. Regulatory factor X, a bare lymphocyte syndrome transcription factor, is amultimeric phosphoprotein complex. J Immunol. 1997;158:5841-5848. (Pubitemid 127483991)
113. Steimle V, Durand B, Barras E, et al. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev. 1995;9:1021-1032.
114. Durand B, Sperisen P, Emery P, et al. RFXAP, a novel subunit of the RFX DNA binding complex is mutated inMHC class II deficiency. EMBO J. 1997;16:1045-1055. (Pubitemid 27113183)
115. Masternak K, Barras E, Zufferey M, et al. A gene encoding a novel RFX-associated transactivator is mutated in themajority of MHC class II deficiency patients. Nat Genet. 1998;20:273-277. (Pubitemid 28507672)
116. Nagarajan UM, Louis-Plence P, DeSandro A, Nilsen R, Bushey A, Boss JM. RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, anMHC class II immunodeficiency. Immunity. 1999;10:153-162. (Pubitemid 29115621)
117. Moreno CS, Beresford GW, Louis-Plence P, Morris AC, Boss JM. CREB regulates MHC class II expression in a CIITA-dependentmanner. Immunity. 1999;10:143-151. (Pubitemid 29115620)
118. Reith W, Siegrist CA, Durand B, Barras E, Mach B. Function of major histocompatibility complex class II promoters requires cooperative binding between factors RFX and NF-Y. Proc Natl Acad Sci U S A. 1994;91:554-558. (Pubitemid 24041440)
119. Lennon AM, Ottone C, Rigaud G, et al. Isolation of a B-cell-specific promoter for the human class II transactivator. Immunogenetics. 1997;45:266-273. (Pubitemid 27077775)
120. Steimle V, Siegrist CA,Mottet A, Lisowska-Grospierre B,Mach B. Regulation ofMHCclass II expression by interferon-gamma mediated by the transactivatr gene CIITA. Science. 1994;265:106-109. (Pubitemid 24253184)
121. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell. 1993;75:135-146. (Pubitemid 23306027)
122. Chen X, Jensen PE. MHC class II antigen presentation and immunological abnormalities due to deficiency ofMHC class II and its associated genes. ExpMol Pathol. 2008;85:40-44.
123. Fischer A.Human primary immunodeficiency diseases: a perspective.Nat Immunol. 2004;5:23-30. (Pubitemid 38081465)
124. ReithW,Mach B.The bare lymphocyte syndrome and the regulation ofMHCexpression. Annu Rev Immunol. 2001;19:331-373. (Pubitemid 32368039)
125. Wolf HM, Hauber I, Gulle H, et al. Twin boys with major histocompatibility complex class II deficiency but inducible immune responses. N Engl JMed. 1995;332:86-90.
126. Uetrecht AC, Bear JE. Coronins: the return of the crown. Trends Cell Biol. 2006;16:421-426. (Pubitemid 44118779)
127. FogerN, Rangell L, DanilenkoDM, Chan AC. Requirement for coronin 1 in T lymphocyte trafficking and cellular homeostasis. Science. 2006;313:839-842. (Pubitemid 44223353)
128. Shiow LR, Roadcap DW, Paris K, et al. The actin regulator coronin 1A is mutant in a thymic egressdeficient mouse strain and in a patient with severe combined immunodeficiency. Nat Immunol. 2008;9:1307-1315.
129. Ochs HD, Notarangelo LD. Structure and function of the Wiskott-Aldrich syndrome protein. Curr Opin Hematol. 2005;12:284-291. (Pubitemid 41058392)
130. Shiow LR, Paris K, Akana MC, Cyster JG, Sorensen RU, Puck JM. Severe combined immunodeficiency (SCID) and attention deficit hyperactivity disorder (ADHD) associated with a Coronin-1A mutation and a chromosome 16p11.2 deletion. Clin Immunol. 2009;131:24-30.
131. Ahmed Z, Shaw G, Sharma VP, Yang C,McGowan E, Dickson DW. Actin-binding proteins coronin- 1a and IBA-1 are effective microglial markers for immunohistochemistry. J Histochem Cytochem. 2007;55:687-700. (Pubitemid 46981767)
132. Ruusala A, Aspenstrom P. Isolation and characterisation of DOCK8, a member of the DOCK180- related regulators of cellmorphology. FEBS Lett. 2004;572:159-166. (Pubitemid 39092529)
133. Cote JF,Vuori K. Identification of an evolutionarily conserved superfamily ofDOCK180-related proteins with guanine nucleotide exchange. J Cell Sci. 2002;115:4901-4913. (Pubitemid 36054642)
134. Yang J, Zhang Z, Roe SM, Marshall CJ, Barford D. Activation of Rho GTPases by DOCK exchange factors is mediated by a nucleotide sensor. Science. 2009;325:1398-1402.
135. Engelhardt KR,McGhee S,Winkler S, et al. Large deletions and pointmutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol. 2009;124:1289-1302.
136. De Silva MG, Elliott K, Dahl HH, et al. Disruption of a novel member of a sodium/hydrogen exchanger family and DOCK3 is associated with an attention deficit hyperactivity disorder-like phenotype. JMed Genet. 2003;40:733-740. (Pubitemid 37311071)
137. Watabe-Uchida M, John KA, Janas JA, Newey SE, Van Aelst L. The Rac activator DOCK7 regulates neuronal polarity through local phosphorylation of stathmin/Op18. Neuron. 2006;51:727-739. (Pubitemid 44374902)
138. Govek EE, Newey SE, Van Aelst L. The role of the Rho GTPases in neuronal development. Genes Dev. 2005;19:1-49. (Pubitemid 40095815)
139. Benarroch EE. Rho GTPases: role in dendrite and axonal growth, mental retardation, and axonal regeneration. Neurology. 2007;68:1315-1318. (Pubitemid 46625980)
140. Bouma G, Burns SO, Thrasher AJ. Wiskott-Aldrich syndrome: immunodeficiency resulting from defective cell migration and impaired immunostimulatory activation. Immunobiology. 2009;214:778-790.
141. Pignata C, Fiore M, Guzzetta V, et al. Congenital alopecia and nail dystrophy associated with severe functional T-cell immunodeficiency in two sibs. AmJMed Genet. 1996;65:167-170.
142. Pignata C. A lesson to unraveling complex aspects of novel immunodeficiencies from the human equivalent of the nude/SCID phenotype. J Hematother Stem Cell Res. 2002;11:409-414. (Pubitemid 34309534)
143. Frank J, Pignata C, Panteleyev AA, et al. Exposing the human nude phenotype. Nature. 1999;398:473-474. (Pubitemid 129523577)
144. FestingMFW,May D, Connors TA, LovellD, SparrowS.Anathymicnudemutation inthe rat.Nature. 1978;274:365-366.
145. Huth M, Schlake T, Boehm T. Transposon-induced splicing defect in the rat nude gene. Immunogenetics. 1997;45:282-283. (Pubitemid 27077779)
146. HofmannM, HarrisM, Juriloff D, Boehm T. Spontaneousmutations in SELH/Bcmice due to insertions of early transposons: molecular characterization of null alleles at the nude and albino loci. Genomics. 1998;52:107-109. (Pubitemid 28452177)
147. Auricchio L, Adriani M, Frank J, Busiello R, Christiano A, Pignata C. Nail distrophy associated with a heterozygous mutation of the Nude/SCID human FOXN1 (WHN) gene. Arch Dermatol. 2005;141:647-648. (Pubitemid 40656081)
148. LeeD,ProwseDM,Brissette JL. Association betweenmousenude gene expression and the initiation of epithelial terminal differentiation. Dev Biol. 1999;208:362-374. (Pubitemid 29183996)
149. Mecklenburg L, Paus R, Halata Z, Bechtold LS, Fleckman P, Sundberg JP. FOXN1 is critical for onycholemmal terminal differentiation in nude (Foxn1) mice. J Invest Dermatol. 2004;123:1001-1011. (Pubitemid 39586818)
150. AdrianiM,Martinez-Mir A, Fusco F, et al. Ancestral foundermutation of the nude (FOXN1) gene in congenital severe combined immunodeficiency associated with alopecia in southern Italy population. Ann HumGenet. 2004;68:265-268. (Pubitemid 39162739)
151. Amorosi S, D'Armiento M, Calcagno G, et al. FOXN1 homozygous mutation associated with anencephaly and severe neural tube defect in human athymic Nude/SCID fetus. Clin Genet. 2008;73:380-384. (Pubitemid 351386999)
152. Henderson RS, McEwan B and Pantelouris EM. Pitutary and cerebellum of nude mice. Thymus. 1981;3:359-368.
153. Pignata C, Gaetaniello L,Masci AM, et al. Human equivalent of the mouse nude/SCID phenotype: long-term evaluation of immunological reconstitution after bone marrow transplantation. Blood. 2001;97:880-885. (Pubitemid 32154269)
154. Gross TG, Shiramizu B. Lymphoproliferative disorders and malignancies related to immunodeficiencies. In: Pizzo PA, PoplackDG, eds. Principles and Practice of PediatricOncology. Philadelphia: LippincottWilliams & Wilkins; 2005.
155. Filipovich AH,Mathur A, Kamat D, Kersey JH, Shapiro RS. Lymphoproliferative disorders and other tumors complicating immunodeficiencies. Immunodeficiency. 1994;5:91-112. (Pubitemid 24122263)
156. Mueller BU, Sei S, Anderson B, et al. Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus. J Pediatr. 1996;129:410-418. (Pubitemid 27484148)
157. Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hematologicalmalignancies. Ann Oncol. 2007;18 (Suppl 1):i3-i8.
158. Rezaei N, HedayatM, Aghamohammadi A, Nichols KE. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. J Allergy Clin Immunol. 2011;127:1329-1341.
159. Notarangelo LD. PIDs and cancer: an evolving story. Blood. 2010;116:1189-1190.
160. Yong PF, Tarzi M, Chua I, Grimbacher B, Chee R. Common variable immunodeficiency: an update on etiology and management. Immunol Allergy Clin North Am. 2008;28:367-386. (Pubitemid 351522413)
161. Poodt AE, Driessen GJ, de Klein A, van Dongen JJ, van der BurgM, de Vries E. TACImutations and disease susceptibility in patients with common variable immunodeficiency. Clin Exp Immunol. 2009;156:35-39.
162. vanZelmMC,Smet J,AdamsB, et al.CD81gene defect inhumans disruptsCD19 complex formation and leads to antibody deficiency. J Clin Invest. 2010;120:1265-1274.
163. Pozzi N,Gaetaniello L,Martire B, et al.Defective surface expression of attractin on T cells in patients with common variable immunodeficiency (CVID). Clin Exp Immunol. 2001;123:99-104. (Pubitemid 32118844)
164. Taylor AM, Metcalfe JA, Thick J, Mak YF. Leukemia and lymphoma in ataxia telangiectasia. Blood. 1996;87:423-438. (Pubitemid 26030297)
165. Vigliano I, Fusco A, Palamaro L, et al. g Chain transducing element: a shared pathway between endocrine and immune system. Cell Immunol. 2011;269:10-15.
166. Zenatti PP, Ribeiro D, Li W, et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet. 2011;43:932-939.
167. Uckun FM, Pitt J, Qazi S. JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2011;11:37-48.
168. Amman AJ,WaraDW, Pillarisetty RJ, TalalN.The prevalence of autoantibodies in T-cell, and phagocytic immunodeficiency disorders. Clin Immunol Immunopathol. 1979;14:456-466. (Pubitemid 10161800)
169. Carneiro-Sampaio M, Coutinho A. Tolerance and autoimmunity: lessons at the bedside of primary immunodeficiencies. Adv Immunol. 2007;95:51-82. (Pubitemid 47380503)
170. Notarangelo LD, Gambineri E, Badolato R. Immunodeficiencies with autoimmune consequences. Adv Immunol. 2006;89:321-370. (Pubitemid 44294561)
171. Fairweather D, Kaya Z, Shellan GR, Lawson CM, Rose NR. From infection to autoimmunity. J Autoimmune. 2001;16:341-345.
172. Westerberg LS, Klein C, Snapper SB. Breakdown of T cell tolerance and autoimmunity in primary immunodeficiency: lessons learned from monogenic disorders in mice and men. Curr Opin Immunol. 2008;20:646-654.
173. Omenn GS. Familial reticuloendotheliosis with eosinophilia. N Engl JMed. 1965;273:427-432.
174. Villa A, Sobacchi C, Notarangelo LD, et al. V(D)J recombination defects in lymphocytes: a severe immunodeficiency with a spectrum of clinical presentations due to RAG mutations. Blood. 2001;97:81-88. (Pubitemid 32061245)
175. Fiore M, Pera C, Delfino L, Scotese I, Ferrara GB, C. P. DNA typing of DQ and DR alleles in IgAdeficient subjects. Eur J Immunogenet. 1995;22:403-411.
176. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92:34-48. (Pubitemid 29315984)
177. Uluhan A, SagerD, Jasin HE. Juvenile rheumatoid arthritis and common variable hypogammaglobulinemia. J Rheumatol. 1998;25:1205-1210. (Pubitemid 28350899)
178. Ochs HD.TheWiskott-Aldrich syndrome. IsraelMed As J. 2002;4:379-384. (Pubitemid 34477014)
179. Levy J, Espanol-Boren T,Thomas C, et al. Clinical spectrumof X-linked hyper-IgM syndrome. J Pediatr. 1997;131:47-54. (Pubitemid 27498308)
180. Cunningham-Rundles C. Clinical and immunologic analyses of 103 patientswith common variable immunodeficiency. J Clin Immunol. 1989;9:22-33. (Pubitemid 19058981)
181. Meffre E,Wardemann H. B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol. 2008;20:632-638.